Pharmaceuticals & Drugs · Founded 1936 · www.amrutanjan.com · BSE 590006 · NSE AMRUTANJAN · ISIN INE098F01031
No Notes Added Yet
1. Business Overview
Amrutanjan Health Care Ltd. is an Indian consumer healthcare company primarily engaged in the manufacturing and marketing of Ayurvedic and Over-The-Counter (OTC) products. Established in 1893, it is one of India's oldest companies in its segment. Its core business revolves around providing relief-oriented products for common ailments like pain, cold, and cough, alongside a growing portfolio of health and wellness products. The company makes money by selling these products through an extensive distribution network across India, including pharmacies, general stores, and modern trade channels, leveraging its strong brand heritage.
2. Key Segments / Revenue Mix
Amrutanjan's business is broadly categorized into:
Pain Management: This is the flagship segment, dominated by products like Amrutanjan Pain Balm, Joint Muscle Spray, and creams for various types of pain. This segment typically contributes the largest share of revenue.
Cough & Cold: Includes products like Amrutanjan Cold Rub and roll-ons designed to alleviate cold and flu symptoms.
Health & Wellness: This growing segment encompasses products such as Fruitnik health drinks, hand sanitizers, and other personal care items, aiming to diversify beyond traditional relief products.
Exact percentage contributions vary year-on-year, but Pain Management historically remains the dominant revenue driver.
3. Industry & Positioning
Amrutanjan operates within the highly competitive Indian consumer healthcare and OTC pharmaceuticals market. This industry is characterized by a mix of large multinational corporations, domestic FMCG giants, and specialized Ayurvedic players. Amrutanjan holds a strong legacy position, particularly in the pain relief balm category, where its brand is a household name. It competes with players like Emami (Zandu Balm), Reckitt Benckiser (Moov), P&G (Vicks), Dabur, and Himalaya. Its positioning is built on a century-old heritage, trust in Ayurvedic formulations, and extensive distribution reach, especially in semi-urban and rural areas.
4. Competitive Advantage (Moat)
Amrutanjan possesses several durable competitive advantages:
Brand Recognition & Heritage: Over 125 years of existence has built immense brand recall and trust, particularly for its pain balms, making "Amrutanjan" almost synonymous with the product category for many consumers.
Extensive Distribution Network: A deep and wide distribution network across India ensures product availability even in remote locations, a significant barrier to entry for new players.
Consumer Loyalty: Generations of consumers have used and trusted Amrutanjan products, leading to strong brand loyalty, especially for its core offerings.
Formulation Expertise: A long history of developing and refining Ayurvedic formulations gives it credibility in traditional remedies.
5. Growth Drivers
Key factors that can drive Amrutanjan's growth include:
Increasing Health & Wellness Awareness: Growing consumer focus on preventive healthcare and natural remedies fuels demand for its Ayurvedic and wellness products.
Product Portfolio Expansion: Launching new products in existing categories (e.g., specialized pain relief) and expanding into adjacent health and hygiene segments.
Deepening Market Penetration: Further expanding its distribution reach into untapped rural markets and strengthening presence in modern retail and e-commerce channels.
Premiumization: Introducing higher-value or specialized products that command better margins.
Demographic Shifts: An aging population could increase demand for pain management solutions.
6. Risks
Intense Competition: Facing stiff competition from well-funded domestic and international FMCG and pharmaceutical companies that have vast marketing budgets and distribution capabilities.
Raw Material Price Volatility: Fluctuations in the prices of key Ayurvedic and natural ingredients can impact production costs and profitability.
Changing Consumer Preferences: A shift towards modern medicine, different forms of natural remedies, or alternative wellness trends could impact demand for traditional products.
Regulatory Changes: Any changes in regulations related to manufacturing, marketing, or labeling of Ayurvedic and OTC products in India.
Counterfeit Products: Risk of fake products eroding brand trust and market share.
7. Management & Ownership
Amrutanjan Health Care Ltd. is a promoter-driven company, with the Sambhu Prasad family holding a significant stake and actively involved in its management. Mr. S. Sambhu Prasad serves as the Chairman and Managing Director. The management is generally perceived as conservative, focused on sustainable growth, and maintaining the company's long-standing heritage. The promoter holding typically hovers around 50-60%, indicating strong family control and alignment with long-term vision.
8. Outlook
Amrutanjan Health Care has a resilient business built on a foundation of strong brand equity and an extensive distribution network, particularly for its heritage pain management products. The company is strategically diversifying its product portfolio into the growing health and wellness segment, which offers avenues for future growth beyond its traditional core. While it operates in a highly competitive market against larger players, its established brand trust and Ayurvedic legacy provide a distinct advantage. The outlook suggests steady, albeit potentially moderate, growth driven by an expanding product range and increasing consumer demand for accessible, trusted healthcare solutions, balanced by the need to innovate and compete effectively against agile rivals.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 117 | 127 | 84 | 110 | 123 | 135 | 94 | 118 | 141 | 150 |
| Other Income | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 5 |
| Total Income | 121 | 132 | 88 | 114 | 127 | 140 | 98 | 122 | 145 | 154 |
| Total Expenditure | 95 | 111 | 80 | 96 | 99 | 118 | 86 | 101 | 116 | 124 |
| Operating Profit | 25 | 21 | 8 | 18 | 28 | 23 | 13 | 21 | 29 | 30 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -8 |
| Profit Before Tax | 24 | 20 | 6 | 16 | 26 | 21 | 11 | 19 | 26 | 21 |
| Provision for Tax | 6 | 6 | 2 | 4 | 7 | 6 | 3 | 5 | 7 | 5 |
| Profit After Tax | 17 | 14 | 5 | 12 | 19 | 15 | 8 | 14 | 19 | 16 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 |
| Profit After Adjustments | 17 | 14 | 5 | 12 | 19 | 15 | 8 | 14 | 19 | 16 |
| Adjusted Earnings Per Share | 6 | 4.7 | 1.6 | 4.1 | 6.7 | 5.3 | 2.9 | 4.8 | 6.7 | 5.6 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 163 | 184 | 212 | 220 | 253 | 261 | 333 | 406 | 380 | 421 | 452 | 503 |
| Other Income | 5 | 6 | 7 | 8 | 7 | 8 | 19 | 17 | 15 | 16 | 18 | 17 |
| Total Income | 168 | 190 | 219 | 228 | 261 | 270 | 352 | 423 | 394 | 438 | 469 | 519 |
| Total Expenditure | 139 | 153 | 182 | 192 | 222 | 231 | 266 | 328 | 335 | 369 | 394 | 427 |
| Operating Profit | 29 | 37 | 37 | 36 | 38 | 39 | 86 | 95 | 59 | 68 | 76 | 93 |
| Interest | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 7 | 8 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9 |
| Profit Before Tax | 26 | 35 | 34 | 33 | 35 | 34 | 82 | 91 | 54 | 62 | 69 | 77 |
| Provision for Tax | 9 | 12 | 12 | 13 | 10 | 9 | 21 | 23 | 14 | 17 | 18 | 20 |
| Profit After Tax | 17 | 22 | 22 | 20 | 25 | 25 | 61 | 67 | 40 | 45 | 51 | 57 |
| Adjustments | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 17 | 22 | 22 | 20 | 25 | 25 | 61 | 67 | 40 | 45 | 51 | 57 |
| Adjusted Earnings Per Share | 5.9 | 7.7 | 7.5 | 6.9 | 8.4 | 8.6 | 20.9 | 23 | 13.6 | 15.6 | 17.6 | 20 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 7% | 4% | 12% | 11% |
| Operating Profit CAGR | 12% | -7% | 14% | 10% |
| PAT CAGR | 13% | -9% | 15% | 12% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -23% | -3% | -6% | 10% |
| ROE Average | 17% | 15% | 21% | 19% |
| ROCE Average | 23% | 21% | 29% | 28% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 105 | 120 | 116 | 129 | 146 | 159 | 216 | 265 | 291 | 288 | 327 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2 | 3 | 1 | 1 | 2 | 2 | 3 | 4 | 4 | 5 | 7 |
| Total Current Liabilities | 23 | 25 | 32 | 32 | 36 | 39 | 52 | 77 | 63 | 70 | 85 |
| Total Liabilities | 130 | 149 | 149 | 162 | 183 | 201 | 271 | 346 | 358 | 364 | 418 |
| Fixed Assets | 13 | 22 | 27 | 28 | 26 | 26 | 23 | 28 | 49 | 50 | 49 |
| Other Non-Current Assets | 39 | 32 | 13 | 13 | 18 | 49 | 25 | 43 | 49 | 18 | 78 |
| Total Current Assets | 79 | 95 | 108 | 121 | 140 | 126 | 223 | 275 | 260 | 296 | 291 |
| Total Assets | 130 | 149 | 149 | 162 | 183 | 201 | 271 | 346 | 358 | 364 | 418 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 29 | 31 | 22 | 10 | 11 | 15 | 7 | 3 | 2 | 5 | 4 |
| Cash Flow from Operating Activities | 19 | 21 | 8 | 19 | 21 | 18 | 91 | 52 | 20 | 28 | 51 |
| Cash Flow from Investing Activities | -5 | 1 | -0 | -8 | -11 | -14 | -88 | -36 | -2 | 19 | -31 |
| Cash Flow from Financing Activities | -12 | -11 | -5 | -9 | -7 | -12 | -7 | -17 | -15 | -48 | -13 |
| Net Cash Inflow / Outflow | 2 | 12 | 3 | 2 | 3 | -7 | -4 | -1 | 3 | -1 | 6 |
| Closing Cash & Cash Equivalent | 31 | 42 | 25 | 11 | 15 | 7 | 3 | 2 | 5 | 4 | 10 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 5.86 | 7.67 | 7.46 | 6.86 | 8.39 | 8.58 | 20.93 | 22.99 | 13.63 | 15.56 | 17.58 |
| CEPS(Rs) | 6.66 | 8.53 | 8.44 | 7.85 | 9.5 | 10.07 | 22.19 | 24.28 | 15.41 | 17.65 | 19.84 |
| DPS(Rs) | 1.75 | 1.93 | 1.93 | 1.95 | 2.15 | 2.1 | 4.2 | 4.6 | 4.6 | 4.6 | 4.6 |
| Book NAV/Share(Rs) | 35.87 | 41.22 | 39.59 | 44.01 | 49.86 | 54.54 | 73.53 | 90.49 | 99.12 | 99.92 | 112.83 |
| Core EBITDA Margin(%) | 14.37 | 16.33 | 13.41 | 12.77 | 12.21 | 11.79 | 20.2 | 19.11 | 11.73 | 12.32 | 12.91 |
| EBIT Margin(%) | 15.75 | 17.99 | 15.41 | 15.02 | 13.77 | 13.31 | 24.79 | 22.46 | 14.19 | 14.77 | 15.37 |
| Pre Tax Margin(%) | 15.39 | 17.89 | 15.16 | 14.88 | 13.69 | 13.18 | 24.61 | 22.32 | 14.13 | 14.71 | 15.3 |
| PAT Margin (%) | 9.98 | 11.6 | 9.82 | 9.05 | 9.67 | 9.59 | 18.38 | 16.56 | 10.49 | 10.68 | 11.25 |
| Cash Profit Margin (%) | 11.36 | 12.91 | 11.12 | 10.36 | 10.96 | 11.26 | 19.49 | 17.49 | 11.87 | 12.11 | 12.7 |
| ROA(%) | 13.45 | 16.07 | 14.66 | 12.89 | 14.18 | 13.05 | 25.94 | 21.78 | 11.32 | 12.47 | 13 |
| ROE(%) | 16.97 | 19.9 | 18.46 | 16.41 | 17.87 | 16.44 | 32.69 | 28.03 | 14.37 | 15.54 | 16.53 |
| ROCE(%) | 26.06 | 30.86 | 28.65 | 26.95 | 25.43 | 22.8 | 44 | 37.93 | 19.38 | 21.47 | 22.58 |
| Receivable days | 53.45 | 49.61 | 45.1 | 46.65 | 43.86 | 41.46 | 24.19 | 25.15 | 34.26 | 35.05 | 41.89 |
| Inventory Days | 14.77 | 14.28 | 14.75 | 16.79 | 17.96 | 26.73 | 22.58 | 19.54 | 26.36 | 25.01 | 22.69 |
| Payable days | 79.48 | 80.83 | 71.56 | 98.06 | 86.35 | 95.43 | 93.75 | 102.26 | 108.19 | 89 | 102.13 |
| PER(x) | 40.85 | 27.21 | 39.57 | 39.2 | 37.05 | 38.45 | 27.15 | 34.53 | 42.19 | 39.77 | 36.67 |
| Price/Book(x) | 6.67 | 5.06 | 7.45 | 6.11 | 6.23 | 6.05 | 7.73 | 8.77 | 5.8 | 6.19 | 5.72 |
| Dividend Yield(%) | 0.73 | 0.92 | 0.65 | 0.73 | 0.69 | 0.64 | 0.74 | 0.58 | 0.8 | 0.74 | 0.71 |
| EV/Net Sales(x) | 4.05 | 3.05 | 3.94 | 3.24 | 3.26 | 3.55 | 4.57 | 5.5 | 4.24 | 4.18 | 3.94 |
| EV/Core EBITDA(x) | 22.54 | 15.07 | 22.52 | 19.71 | 21.68 | 23.71 | 17.66 | 23.51 | 27.26 | 25.82 | 23.44 |
| Net Sales Growth(%) | 17.64 | 12.89 | 14.77 | 3.96 | 15.17 | 3.2 | 27.29 | 21.93 | -6.46 | 10.96 | 7.26 |
| EBIT Growth(%) | 17.63 | 28.73 | -1.64 | -2.71 | 4.87 | -0.27 | 137.11 | 10.5 | -40.91 | 15.46 | 11.68 |
| PAT Growth(%) | 17.85 | 30.98 | -2.76 | -8.03 | 22.27 | 2.32 | 143.95 | 9.8 | -40.71 | 12.9 | 13.03 |
| EPS Growth(%) | 17.85 | 30.98 | -2.76 | -8.03 | 22.27 | 2.32 | 143.95 | 9.8 | -40.71 | 14.15 | 13.04 |
| Debt/Equity(x) | 0 | 0 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 3.42 | 3.76 | 3.35 | 3.75 | 3.87 | 3.22 | 4.28 | 3.55 | 4.13 | 4.23 | 3.44 |
| Quick Ratio(x) | 3.1 | 3.44 | 3.04 | 3.43 | 3.46 | 2.61 | 3.94 | 3.21 | 3.67 | 3.82 | 3.11 |
| Interest Cover(x) | 43.76 | 173.68 | 61.33 | 106.83 | 172.19 | 102.57 | 139.35 | 156.66 | 241.99 | 247.9 | 213 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.59 | 50.59 | 50.59 | 46.52 | 46.52 | 46.52 | 46.52 | 46.52 | 46.52 | 46.52 |
| FII | 0.8 | 1.38 | 1.55 | 2.34 | 2.3 | 2.3 | 2.41 | 2.38 | 2.27 | 2.17 |
| DII | 7.24 | 7.29 | 7.32 | 10.6 | 11.12 | 11.41 | 12.7 | 12.9 | 13 | 12.66 |
| Public | 41.37 | 40.74 | 40.54 | 40.54 | 40.06 | 39.78 | 38.37 | 38.2 | 38.21 | 38.65 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.46 | 1.46 | 1.46 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 |
| FII | 0.02 | 0.04 | 0.04 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.06 |
| DII | 0.21 | 0.21 | 0.21 | 0.31 | 0.32 | 0.33 | 0.37 | 0.37 | 0.38 | 0.37 |
| Public | 1.2 | 1.18 | 1.17 | 1.17 | 1.16 | 1.15 | 1.11 | 1.1 | 1.1 | 1.12 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +7% | +4% | +12% | +11% |
| Operating Profit CAGR | +12% | -7% | +14% | +10% |
| PAT CAGR | +13% | -9% | +15% | +12% |
| Share Price CAGR | -23% | -3% | -6% | +10% |
| ROE Average | +17% | +15% | +21% | +19% |
| ROCE Average | +23% | +21% | +29% | +28% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.59 | 50.59 | 50.59 | 46.52 | 46.52 | 46.52 | 46.52 | 46.52 | 46.52 | 46.52 |
| FII | 0.8 | 1.38 | 1.55 | 2.34 | 2.3 | 2.3 | 2.41 | 2.38 | 2.27 | 2.17 |
| DII | 7.24 | 7.29 | 7.32 | 10.6 | 11.12 | 11.41 | 12.7 | 12.9 | 13 | 12.66 |
| Public | 49.41 | 49.41 | 49.41 | 53.48 | 53.48 | 53.48 | 53.48 | 53.48 | 53.48 | 53.48 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.46 | 1.46 | 1.46 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 |
| FII | 0.02 | 0.04 | 0.04 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.06 |
| DII | 0.21 | 0.21 | 0.21 | 0.31 | 0.32 | 0.33 | 0.37 | 0.37 | 0.38 | 0.37 |
| Public | 1.43 | 1.43 | 1.43 | 1.55 | 1.55 | 1.55 | 1.55 | 1.55 | 1.55 | 1.55 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 | 2.89 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.